mixtures
News
14.03.2016
Merck Initiates Phase III Study of MSB11022
Merck, a leading science and technology company, today announced the initiation of a global Phase III clinical study of MSB11022, a proposed biosimilar of adalimumab, in chronic plaque psoriasis. This […]
18.05.2016
Almirall’s Q1 results 2016: on track to achieve yearly guidance
– Net Sales +2.7%, benefiting from contribution of new businesses – Growth driven by Dermatology +13.3%, which now accounts for 43% of sales vs. 39% in Q1 15 – Product […]
31.05.2018
Cutera Announces Opening of New Office and Training Center in Madrid
CUTERA, INC., (Nasdaq:CUTR) (“Cutera” or the “Company”) a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, announces the opening of its new office and training […]